Yan Ming

Yan Ming, Chief Technology Officer of Cytek Biosciences (CTKB), has demonstrated a consistent pattern of selling activity based on SEC Form 4 filings, with no recorded purchases across 27 reported transactions. Since August 2025, Ming has exclusively executed sales under code "F" (representing dispositions to satisfy tax withholding obligations), totaling $85,987.60 in aggregate value. The transactions have occurred quarterly, with the most recent activity on March 10, 2026, when Ming sold shares worth $10,139.31, $9,674.01, and $12,888.81 in separate filings. Earlier dispositions include a $1,659 sale on February 18, 2026, and multiple transactions in November and August 2025 ranging from $2,670.99 to $9,915.29 per filing. The filings indicate these sales are tied to tax-related dispositions rather than open market transactions, as evidenced by the consistent "F" code alongside "M" codes denoting exempt acquisitions. While the dollar amounts per transaction remain modest—typically between $5,000 and $13,000—the quarterly cadence suggests a structured approach to meeting tax obligations. Ming’s activity is concentrated solely in CTKB, with no trades reported in other securities. The absence of any buy transactions and the recurring nature of these dispositions highlight a predictable pattern tied to equity compensation events rather than discretionary trading.